| Literature DB >> 25888423 |
Amine Souadka1, Mohammed Anass Majbar2, Tijani El Harroudi3, Amine Benkabbou3, Abdelilah Souadka3,4.
Abstract
BACKGROUND: The aim of this study was to evaluate oncologic results and satisfaction rate results of pseudocontinent perineal colostomy (PCPC) using Schmidt's technique in patients undergoing abdominoperineal resection (APR) for managing low rectal adenocarcinoma.Entities:
Mesh:
Year: 2015 PMID: 25888423 PMCID: PMC4406037 DOI: 10.1186/s12893-015-0027-z
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Figure 1Excision of the specimen by a perineal approach.
Figure 2Colic graft preparation. a: Stripping from its meso and epiploics. b: Stripping from its mucosa.
Figure 3Suture of the enrolled graft around the colon.
Figure 4Final aspect of the PCPC.
Population characteristics
|
|
|
|---|---|
| Gender | 71 M/75 F |
| Mean age ± SD (years) | 47 ± 10,4 (21–76) |
| CPC after | |
| Classic APR | 114 |
| Posterior pelvic exenteration | 27 |
| Total exenteration | 2 |
| In second step (after LQIC) | 3 |
| Preoperative radiotherapy | |
| • Alone (before 2000) | 94 (64) |
| • Combined to chemotherapy | 52 (36) |
| Tumour stage (UICC) | |
| I | 22 (15%) |
| II | 64 (43.8) |
| III | 44 (30.1) |
| IV | 8 (5.5) |
| Non precised | 8 (5.5) |
| Postoperative mortality | 0 |
| Postoperative morbidity | 24 (16.4) |
UICC: international Union against cancer (2002) 6th edition.
Figure 5Overall survival of 146 patients after APR and PCPC for low rectal adenocarcinoma.
Figure 6Disease free survival of 146 patients after APR and PCPC for low rectal adenocarcinoma.
details of satisfaction rate, functional and oncologicial results of 146 PCPC
|
| |
|---|---|
| Kirwan stage of continence | |
| • A and B | 100 |
| • C, D and E | 46 |
| Satisfaction rate at the latest visit | |
| • Highly satisfied (8–10) | 112 (77) |
| • Satisfied (4–7) | 33 (22,4) |
| • Unsatisfied (0–3) | 1 (0,6) |
| Oncological results | |
| • Median follow up of months | 36 months (range 12–156) |
| • 5-year Overall survival rate | 74,6% |
| • 5-year disease free survival | 60,3% |